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Summary
 
Mice deficient in the cytokines tumor necrosis factor (TNF) or lymphotoxin (LT) 
 
a
 
/
 
b
 
 lack
polarized B cell follicles in the spleen. Deficiency in CXC chemokine receptor 5 (CXCR5), a
receptor for B lymphocyte chemoattractant (BLC), also causes loss of splenic follicles. Here we
report that BLC expression by follicular stromal cells is defective in TNF-, TNF receptor 1
(TNFR1)-, LT
 
a
 
- and LT
 
b
 
-deficient mice. Treatment of adult mice with antagonists of
LT
 
a
 
1
 
b
 
2 also leads to decreased BLC expression. These findings indicate that LT
 
a
 
1
 
b
 
2 and
TNF have a role upstream of BLC/CXCR5 in the process of follicle formation. In addition to
disrupted follicles, LT-deficient animals have disorganized T zones. Expression of the T cell at-
tractant, secondary lymphoid tissue chemokine (SLC), by T zone stromal cells is found to be
markedly depressed in LT
 
a
 
-, and LT
 
b
 
-deficient mice. Expression of the SLC-related chemo-
kine, Epstein Barr virus–induced molecule 1 ligand chemokine (ELC), is also reduced. Explor-
ing the basis for the reduced SLC expression led to identification of further disruptions in T
zone stromal cells. Together these findings indicate that LT
 
a
 
1
 
b
 
2 and TNF are required for the
development and function of B and T zone stromal cells that make chemokines necessary for
lymphocyte compartmentalization in the spleen.
Key words: lymphoid tissue • follicle • lymphocyte • follicular dendritic cell • dendritic cell
G
 
enetic studies in mice have established that the cyto-
kines TNF, lymphotoxin 
 
a
 
 (LT
 
a
 
),
 
1
 
 and LT
 
b
 
, and the
receptors TNFR1 and LT
 
b
 
R, are required for normal
compartmentalization of lymphocytes in the spleen (1, 2).
In TNF- and TNFR1-deficient mice, follicular dendritic
cells (FDCs) are lacking and B cells fail to form follicular
clusters, instead appearing in a ring at the T zone periphery
(3–6). Mice deficient in LT
 
a
 
, which are deficient in mem-
brane LT
 
a
 
1
 
b
 
2 heterotrimers and soluble LT
 
a
 
3 complexes
(7), show a distinct phenotype that includes absence of
lymph nodes and Peyer’s patches, and loss of marginal zone
cells, FDCs, and normal B/T segregation in white pulp
cords of the spleen (6, 8–10). LT
 
b
 
2
 
/
 
2
 
 mice, which cannot
produce membrane forms of LT that bind LT
 
b
 
R but con-
tinue to express LT
 
a
 
, exhibit a similar phenotype except
that some lymph nodes are retained and splenic architecture
is somewhat less disturbed than in LT
 
a
 
2
 
/
 
2
 
 mice (11, 12;
Korner, H., and J.D. Sedgwick, unpublished observations).
In parallel studies an understanding has begun to develop
of the role played by chemokine receptors and chemokines
in controlling cell movements within lymphoid tissues.
Mice lacking CXCR5 (formerly Burkitt’s lymphoma re-
ceptor 1 [BLR1]), a chemokine receptor expressed by ma-
 
1
 
Abbreviations used in this paper:
 
 BCR, B cell receptor; BLC, B lymphocyte
chemoattractant; DC, dendritic cell; EBI-1, Epstein Barr virus–induced
molecule 1; ELC, EBI-1 ligand chemokine; EF, elongation factor; ES,
embryonic stem; FDC, follicular DC; LT, lymphotoxin; MAdCAM, mu-
cosal addressin cell adhesion molecule; MMM, marginal metallophilic
macrophage; MZM, marginal zone macrophage; RAG, recombination
activating gene; SDF, stromal cell–derived factor; SLC, secondary lym-
phoid tissue chemokine.
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a/b
 
 and TNF Promote Expression of B and T Zone Chemokines
 
ture B cells (13, 14), lack polarized follicles in the spleen
and B cells appear as a ring at the boundary of the T zone
(5). Recently, a CXCR5 ligand, termed B lymphocyte
chemoattractant (BLC) or B cell attracting chemokine
(BCA)-1 (15, 16), has been found constitutively expressed
by stromal cells in lymphoid follicles and has been proposed
to act as a B cell homing chemokine (15). Three other
chemokines have been identified that are constitutively
expressed in lymphoid tissues and that are efficacious attrac-
tants of resting lymphocytes: stromal cell–derived factor 1
(SDF1 [17–19]), secondary lymphoid tissue chemokine
(SLC)/6Ckine (20–24), and EBV-induced molecule 1
ligand chemokine (ELC)/macrophage inflammatory pro-
tein (MIP)-3
 
b 
 
(25–28). SDF1 is an efficacious attractant of
mature lymphocytes (19), although its pattern of expression
in lymphoid tissues is not well characterized. SLC and ELC
are related chemokines that strongly attract naive T cells
and more weakly attract B cells. SLC is expressed by high
endothelial venules (HEVs) in lymph nodes and Peyer’s
patches and by stromal cells in the T zone of spleen, lymph
nodes, and Peyer’s patches (21, 22, 24), whereas ELC is ex-
pressed by T zone DCs (27). The strong chemotactic activ-
ity of SLC and ELC combined with their compartmental-
ized expression pattern has led to the suggestion that these
molecules function in lymphocyte homing to the T zone
of peripheral lymphoid tissues (21, 27).
The strikingly similar disruption of splenic B cell distri-
bution in TNF- and CXCR5-deficient mice suggested that
these molecules act in a common pathway to maintain fol-
licular organization (29). The more severe splenic disrup-
tions in LT
 
a
 
/
 
b
 
-deficient mice suggest LT may function
upstream of molecules that help organize cells into both
follicles and T zones. Here we report that expression of the
CXCR5 ligand, BLC, is substantially reduced in TNF-,
TNFR1-, LT
 
a
 
-, and LT
 
b
 
-deficient mice. Expression of
SLC and ELC is also reduced, whereas SDF1 is unaffected.
Antagonism of LT
 
a
 
1
 
b
 
2 function in the adult by treatment
with soluble LT
 
b
 
R-Ig or anti-LT
 
b
 
 antibody caused reduc-
tions in BLC and SLC expression. We also observed that in
addition to defects in follicular stromal cells, the LT- and
TNF-deficient mice had disruptions in T zone stromal
cells. To identify which cell types may act as sources of the
LT
 
a
 
/
 
b
 
 and TNF required for upregulating BLC expres-
sion, mice lacking subpopulations of hematopoietic cells
were studied. Mice deficient in B cells, which also lack fol-
licular stromal cells, had reduced BLC expression, whereas
T cell and marginal zone macrophage (MZM)-deficient
mice were unaffected. These findings suggest that TNF and
membrane LT
 
a
 
/
 
b
 
 heterotrimer transmit signals required
for the development and function of stromal cells that pro-
duce chemokines essential for normal organization of lym-
phoid tissue compartments.
 
Materials and Methods
 
Animals.
 
TNF
 
2
 
/
 
2
 
, TNF/LT
 
a
 
2
 
/
 
2
 
, and LT
 
a
 
2
 
/
 
2
 
 mice were
generated using C57BL/6 embryonic stem (ES) cells and main-
tained on a pure C57BL/6 background as described (6, 30). A
further strain, generated by targeting of the LT
 
b
 
 gene in Bruce 4
C57BL/6 ES cells (31), was produced. The LT
 
b
 
 gene was dis-
rupted by insertion of the neomycin cassette in reverse orienta-
tion in exon I, leading to complete gene inactivation and typical
LT
 
b
 
2
 
/
 
2
 
 phenotype (Korner, H., D.S. Riminton, F.A. Lemckert,
and J.D. Sedgwick, manuscript in preparation). TNFR1
 
2
 
/
 
2
 
 mice
were generated using C57BL/6 ES cells and were maintained on
a pure C57BL/6 background (32). C57BL/6 
 
op
 
/
 
op
 
, C57BL/6
BCR
 
2
 
/
 
2
 
 (
 
m
 
MT), C57BL/6 TCR-
 
b
 
2
 
/
 
2
 
d
 
2
 
/
 
2
 
, and C57BL/6 re-
combination activating gene (RAG)-1
 
2
 
/
 
2
 
 mice were obtained
from The Jackson Labs. 
 
op
 
/
 
op
 
 mice are toothless and were fed
powdered mouse chow moistened with water. Mice used for sol-
uble LT
 
b
 
R-Ig (33) or anti-LT
 
b
 
 mAb (BB.F6 [34]) treatment
were from a C57BL/6 colony maintained at the University of
California San Francisco. Treatment was with 100 
 
m
 
g of fusion
protein or 200 
 
m
 
g of antibody intraperitoneally once per week as
described previously (35–37). As a control for the LT
 
b
 
R-Ig fu-
sion protein, which contains human IgG1 hinge, C
 
H
 
2 and C
 
H
 
3
regions, mice were treated with a human LFA3-IgG1 hinge, C
 
H
 
2
and C
 
H
 
3 region fusion protein (100 
 
m
 
g/wk, i.p.) as in previous
studies (35, 36). Human LFA3 does not bind to mouse CD2 (8).
The control group for the hamster anti-LT
 
b
 
 mAb–treated mice
were injected with hamster anti-KLH mAb (37).
 
Northern Blot Analysis.
 
10–15 
 
m
 
g of total RNA from mouse
spleens was subjected to gel electrophoresis, transferred to Hy-
bond N
 
1
 
 membranes (Amersham Pharmacia Biotech), and
probed using randomly primed 
 
32
 
P-labeled mouse cDNA probes
of the following types: BLC, bases 10–532 (15); SLC, bases 1–848
(21); ELC, bases 1–755 (27); and SDF1
 
a
 
, bases 30–370 (18). To
control for loading and RNA integrity, membranes were re-
probed with a mouse elongation factor 1
 
a
 
 (EF-1
 
a
 
) probe. For
quantitation, Northern blots were exposed to a phospho screen
for 6 h to 3 d and images were developed using a Storm860
PhosphorImager (Molecular Dynamics). Data were analyzed us-
ing ImageQuant
 
®
 
 software (Molecular Dynamics), and chemo-
kine mRNA levels were corrected for RNA loaded by dividing
the chemokine hybridization signal by the EF-1
 
a
 
 signal for the
same sample. Relative expression levels were calculated by divid-
ing the corrected signal for each mutant or treated sample with
the mean corrected signal for the wild-type or control treated
samples, as appropriate, that were included on each of the North-
ern blots.
 
In Situ Hybridization.
 
For in situ hybridizations, frozen sec-
tions (6 
 
m
 
m) were treated as described (15). In brief, sections
were fixed in 4% paraformaldehyde, washed in PBS, prehybrid-
ized for 1–3 h, and hybridized overnight at 60
 
8
 
C with sense or
antisense digoxigenin-labeled riboprobes in hybridization solu-
tion. After washing at high stringency, sections were incubated
with sheep antidigoxigenin antibody (Boehringer Mannheim)
followed by alkaline phosphatase–coupled donkey anti–sheep an-
tibody (Jackson ImmunoResearch Laboratories) and developed
with NBT (Bio-Rad) and BCIP (Sigma).
 
Immunohistochemistry.
 
Cryostat sections (6–7 
 
m
 
m) were fixed
and stained as described previously (27) using the following
mAbs: rat anti-B220 (RA3-6B2); rat anti-CD4 and -CD8 (Cal-
tag); rat anti-CD35 (8C12; PharMingen); rat anti-MOMA1 (pro-
vided by Georg Kraal, Free University, Amsterdam, The Nether-
lands); and biotinylated mouse anti–BP-3 (38). Rat IgG antibodies
were detected with goat anti–rat-conjugated horseradish peroxi-
dase or alkaline phosphatase (Southern Biotechnology Associates)
and biotinylated antibodies with avidin–alkaline phosphatase
(Sigma Chemical Co.). Enzyme reactions were developed with
conventional substrates for peroxidases (diaminobenzidine/H
 
2
 
O
 
2
 405
 
Ngo et al.
Figure 1. Reduced expres-
sion of lymphoid tissue chemo-
kines in TNF/TNFR1- and
LTa/b-deficient mouse spleen.
(A) Northern blot analysis of to-
tal RNA isolated from spleen tis-
sue of the indicated mice and
probed to detect expression of
BLC, SLC, ELC, and SDF1.
Hybridization to EF-1a was
used to control for RNA loaded.
For SDF1, the hybridization sig-
nals for SDF1a and SDF1b (ref-
erence 18) were similar and the
signal for SDF1a is shown. WT,
wild-type. (B) Relative chemo-
kine mRNA levels as determined
by PhosphorImager analysis of
the Northern blot shown in A
and additional blots, after cor-
recting for differences in RNA
loading from the corresponding
EF-1a value. Data from individ-
ual mice are shown as open cir-
cles and means as shaded bars.
(C) In situ hybridization analysis
of BLC and SLC expression in
spleen from wild-type, TNFR1-
deficient, or LTa-deficient mice.
Original magnification: 310. ca,
central arteriole; F, follicle; T, T
zone. The insets in the BLC and
SLC wild-type control panels are
included to show the morphol-
ogy of the chemokine-express-
ing stromal cells (original magni-
fication: 340).
[Sigma]) and alkaline phosphatase (FAST RED/Naphthol AS-MX
[Sigma] or NBT/BCIP). In some cases, sections were counterstained
with hematoxylin (Fisher Scientific Co.). Sections were mounted
in crystal mount (Biomeda Corp.) and viewed with a Leica DMRL
microscope. Images were acquired on an Optronics MDEI850
cooled CCD video camera (Optronics Engineering) and were
processed with Photoshop software (Adobe Systems, Inc.).
Results
Reduced Chemokine Expression in TNFR1-, TNF-, LTa-,
and LTb-deficient Mice. To explore whether TNF/TNFR1
and CXCR5 function in a common pathway of follicular
organization, we measured CXCR5 expression in TNFR1-
and TNF-deficient mice by flow cytometry. Splenic B cells
from TNF- and TNFR1-deficient mice expressed levels of
CXCR5 that were slightly elevated compared with wild-
type controls (39; Ansel, K.M., and J.G. Cyster, data not
shown). Increased CXCR5 expression seemed unlikely to
account for the disrupted organization of B cells in TNF-
or TNFR1-deficient animals, but could result from reduced
expression of ligands that normally engage and downregu-
late CXCR5. Therefore, we tested whether TNF/TNFR1
regulated CXCR5 ligand expression by measuring BLC
RNA levels in TNF- and TNFR1-deficient mouse spleens
(Fig. 1, A and B). BLC expression was reduced approxi-
mately threefold in both types of mutant mice compared
with wild-type littermates. In situ hybridization analysis of
TNFR1-deficient spleen confirmed the reduced expression
of BLC by follicular stromal cells (Fig. 1 C). Animals defi-
cient in LTa or LTb also lack follicles and follicular stro-
mal cells, although the absence of MZMs and the severely
disrupted B/T boundary make the splenic phenotype of
these mice distinct. BLC expression was reduced even
more severely in spleens from LTa- and LTb-deficient an-
imals than from TNF-deficient mice (Fig. 1, A and B), and
the residual expression was too low to be detected in in situ
hybridization analysis (Fig. 1 C). In mice deficient in both
LTa and TNF, BLC expression was reduced to an extent
similar to LTa single mutants (Fig. 1, A and B), consistent
with the possibility that these cytokines function in a com-
mon pathway leading to BLC expression.
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Figure 2. Decreased BLC expression in
mice treated with LTa1b2 antagonists. (A)
Relative chemokine mRNA levels as deter-
mined by Northern blot and PhosphorIm-
ager analysis of total spleen RNA from mice
treated for the indicated time period with
LTbR-Ig (100 mg/wk, i.p.) or hamster
anti-LTb mAb (200 mg/wk, i.p.). Control
mice for the LTbR-Ig treatment were
treated with equal doses of LFA3-Ig, and
controls for the mAb treatment were given
hamster anti-KLH mAb. Each sample was
corrected for differences in RNA loading
using the value obtained with an EF-1a
probe. Chemokine expression as percentage
of control was calculated by dividing the
corrected value for each treated mouse with
the mean corrected value for the controls at
that time point. Data from individual mice
are shown as filled circles and means as
shaded bars. (B) Relative chemokine
mRNA levels in spleen and mesenteric
lymph nodes from animals treated for 2 wk
with LTbR-Ig (100 mg/wk, i.p.). Calcula-
tions were made as in A. (C) Disrupted fol-
licular organization in LTbR-Ig–treated
mice. Spleen tissue from mice treated with
LFA3-Ig for 2 wk or LTbR-Ig for 1 or 2
wk was sectioned and stained with B220
(dark gray) to detect B cells.
Splenic T zone organization is also disrupted in the cy-
tokine- and cytokine receptor–deficient animals, ranging
from subtle changes in TNF- and TNFR1-deficient mice
to almost complete loss of T zones in LTa, LTb, and
LTa/TNF double mutant mice. To determine whether
LTa/b and TNF also functioned in a pathway leading to
T zone chemokine expression, we measured the expres-
sion of SLC and ELC, related T cell attracting chemokines
that are made in the T zone. We also measured expression
of the more broadly distributed chemokine, SDF1, which
is an efficacious attractant of both B and T cells. SLC was
reduced in expression z2-fold in TNFR1- and TNF-
deficient animals and .20-fold in LTa, LTb, and LTa/
TNF double mutant animals (Fig. 1, A and B). By in situ
hybridization analysis, the network of SLC expressing
stromal cells remained visible in the TNFR1 mutant mice
but could not be detected in LTa-deficient animals (Fig. 1
C). Expression of ELC was also reduced in all of the mu-
tant strains, although less severely than SLC (Fig. 1, A and
B). By contrast, SDF1 expression was not significantly re-
duced in any of the mutant animals (Fig. 1, A and B), indi-
cating that the reductions in BLC, SLC, and ELC are
physiologically relevant and not the result of an overall
decrease in chemokine gene expression. It should be em-
phasized that the TNFR1 mutant and the four cytokine
mutants used in this study (6, 30, 32; Korner, H., D.S.
Riminton, F.A. Lemckert, and J.D. Sedgwick, unpub-
lished) were all generated using C57BL/6 ES cells and
maintained on a C57BL/6 background, making it unlikely
that any of the differences we observed in chemokine
expression are due to linked genetic differences. There-
fore, these experiments demonstrate that TNF/TNFR1
and LTa/b are required for normal expression of BLC,
SLC, and ELC in the spleen.
Treatment of Adult Mice with LTa/b Antagonists Dimin-
ishes Chemokine Expression. To determine whether the re-
quirement for LTa and LTb in the expression of BLC and
SLC was developmental or constitutive, we treated adult
mice for various time periods with soluble LTbR-Ig fusion
protein (8, 40), an antagonist of LTa1b2, and a related
molecule, LIGHT (41). Control mice were treated for
equal periods of time with an LFA3-Ig fusion protein (8).
After 1 wk of LTbR-Ig treatment, splenic BLC expression
was reduced twofold compared with the controls (Fig. 2
A). A further reduction in BLC expression occurred after 2
wk of treatment and did not become more severe after 3 or
4 wk of treatment (Fig. 2 A). 2 wk of treatment also lead to
decreased BLC levels in mesenteric lymph nodes (Fig. 2 B).
Expression of SLC was reduced in spleen and mesenteric
lymph nodes of mice given LTbR-Ig, although the degree
of inhibition was variable and less severe than the reduction
in BLC (Fig. 2, A and B). To distinguish the possible con-
tribution of LIGHT from that of LTa1b2, mice were
treated for 1 or 2 wk with an anti-LTb mAb that specifi-
cally blocks LTa/b heterotrimer function (37, 40). Analy-
sis of splenic RNA showed that BLC and SLC expression
were both reduced after 2 wk of anti-LTb mAb treatment
(Fig. 2 A). These results establish a key role for LTa1b2 in
maintaining normal chemokine expression. Although the
lesser effect of the antibody treatment compared with
LTbR-Ig treatment (Fig. 2 A) suggests that LIGHT might
also contribute, the results may equally be explained by the
mAb causing less complete inhibition of LTa1b2 function,
as has been observed in in vitro studies (40). To explore
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further the relationship noted in the mutant mice between
chemokine deficiency and loss of follicular organization,
spleen sections from LTbR-Ig–treated mice were stained
for B cell markers as well as FDCs and marginal zone mark-
ers. As observed previously (36), expression of mucosal ad-
dressin cell adhesion molecule (MAdCAM)-1 and FDC
markers were reduced after 1 wk of treatment and were
undetectable by 2 wk, whereas loss of the marginal metal-
lophilic macrophage (MMM) marker MOMA1 was more
gradual (data not shown). Changes in B cell follicular orga-
nization were also observed after 1 wk of treatment (Fig. 2
C) and were maximal after 2 wk of treatment (Fig. 2 C),
paralleling the decrease in BLC expression. These results
establish a constitutive requirement for LTa1b2 in main-
taining normal levels of BLC and SLC. The more modest
decrease in BLC and SLC expression in LTbR-Ig–treated
mice compared with LTa2/2 or LTb2/2 mice could re-
flect incomplete blocking of LTa1b2 function but is also
consistent with a role for LTa1b2 in development that
does not continue in the adult mouse.
TNF- and LTa1b2-dependent Stromal Cells in Follicles and
T Zone. The above experiments demonstrated that TNF,
LTa, and LTb are required for normal expression of the
chemokines BLC and SLC by stromal cells in the spleen.
Several studies have established that the organization of
FDCs is disrupted in TNF-, LTa-, and LTb-deficient
mice (1), indicating that the cell type normally producing
BLC might be disrupted. However, disruption of FDC or-
ganization could not account for the decreased SLC ex-
pression, since FDCs do not extend into the T zone. To
test whether changes in addition to reduced SLC expres-
sion could be detected in T zone stromal cells, we exam-
ined expression of BP-3, a marker for an extensive network
of stromal cells in both the T zone and follicles (38, 42).
Strikingly, the network of BP-31 cells was greatly reduced
in both the B and T zones of TNF- and TNFR1-deficient
mice (Fig. 3, and data not shown) and was undetectable in
LTa- and LTb-deficient mice except for a small number of
cells with altered morphology that were occasionally ob-
served (Fig. 3). The disruption of BP-3–expressing stromal
cells in both TNF- and LTa/b-deficient spleens appeared
more severe than in lymphocyte-deficient (RAG-12/2)
spleens (Fig. 3). BP-3 expression in T zone and follicles was
also markedly disrupted after 1 wk of treatment with
LTbR-Ig or anti-LTb antibody and was almost undetect-
able after 2 wk of treatment (Fig. 3, and data not shown).
This period of treatment is also sufficient to disrupt staining
for MAdCAM-1 and FDC markers (36, 43). To determine
the relationship between BP-3–expressing cells in follicles
and the cell types previously defined as TNF- and LTa and
b–dependent, sections from wild-type mice were double
stained for MAdCAM-1 or CR1 (CD35) and BP-3 (Fig. 4
A). BP-3–expressing cells in the outer follicle appeared to
line the marginal sinus, and in some cases these cells co-
stained for MAdCAM-1 (Fig. 4 A). Many of the BP-31
cells located in the center of the follicle costained with
CD35 (Fig. 4 A), whereas BP-31 cells in other parts of
the follicle, especially cells near the marginal sinus, were
CD35-low or -negative (Fig. 4 A). Therefore, the BP-3–
expressing stromal cell population includes T zone stromal
cells (Fig. 3 and Fig. 4 A), FDCs, marginal sinus lining cells,
and follicular stromal cells that are low or negative for FDC
markers (Fig. 4 A). The severe disruption of BP-3 expres-
sion in the mutant mice, together with the reduced BLC
and SLC expression and the loss of FDCs, indicates that
TNF, LTa, and LTb have a broad role in inducing and
maintaining stromal cell integrity in T zones and B zones of
lymphoid tissues.
MZMs Are Not Required for BLC Production. In addition
to defects in FDCs, MAdCAM-11 cells, and BP-31 cells,
LTa- and LTb-deficient mice also lack MZMs and
MMMs (1, 11, 12). To test the possibility that the defi-
ciency in these macrophage populations in LTa2/2 and
LTb2/2 mice contributed to the greatly reduced BLC ex-
Figure 3. Disruption of BP-3 expression in follicles and T zone of
TNF-, TNFR1-, LTa-, and LTb-deficient mice and LTbR-Ig–treated
mice. Spleen tissue from the indicated mutant mice or mice treated with
soluble LTbR-Ig for 1–2 wk or from a wild-type control was sectioned
and stained to detect T cells (combination of anti-CD4 and anti-CD8;
brown) and BP-3 (red). The CD4 and CD8 staining in the RAG-12/2
spleen does not represent T cells, as there was no staining for CD3 (not
shown). CA, central arteriole; F, follicle; T, T zone. Original magnifica-
tion: 310.
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pression and loss of follicular organization, we characterized
spleens from op/op mice, a strain that is deficient in MMMs
and MZMs due to a mutation in the colony stimulating
factor 1 gene (44, 45). Organization of B cell follicles ap-
peared normal in op/op spleen (Fig. 4 B), and BLC expres-
sion was not reduced (Fig. 5). Expression of BP-3, MAd-
CAM-1, and CD35 was also not disrupted (Fig. 4 B, and
data not shown). These findings demonstrate that MZMs
and MMMs do not make a significant contribution to the
constitutive production of BLC, and also establish that
these cells are not required as a source of TNF or LTa1b2
to maintain BLC expression or follicular organization.
Normal Expression of BLC Is Dependent on B Cells. Re-
cent studies have demonstrated that B lymphocytes are an
essential source of membrane LTa1b2 for establishing
FDC networks and follicular organization (46, 47). How-
ever, mice congenitally deficient in LTa have a more se-
vere disruption of lymphoid compartmentalization than
mice lacking only in lymphocyte LTa expression, indicat-
ing that there is also a nonlymphocyte source of LTa (47,
48). To determine whether either or both sources of LTa
were required for induction of BLC, chemokine expres-
sion levels in RAG-12/2, B cell receptor (BCR)2/2, and
TCR2/2 mice were compared with levels in LTa2/2 ani-
mals. BLC expression was reduced approximately fivefold
in spleens from lymphocyte-deficient (RAG-12/2) and B
cell–deficient (mMT) mice, but were not reduced in T
cell–deficient (TCR-b2/2d2/2) mice (Fig. 5), demonstrat-
ing that B cells are important for induction of BLC expres-
sion, presumably providing LTa1b2 and possibly also
TNF. However, BLC levels in RAG-12/2 and BCR2/2
mice were not reduced to the extent of LTa2/2 or LTb2/2
mice (Fig. 5, and see Fig. 1), indicating that some BLC ex-
pression in the spleen is induced by LTa/b-expressing cells
other than B and T lymphocytes.
Discussion
These studies provide new insight into the mechanism
by which TNF and LTa/b promote normal compartmen-
talization of lymphocytes in the white pulp cords of the
spleen. The findings extend the previously defined require-
ment for TNF and LTa/b in the development and func-
tion of follicular stromal cells to also include stromal cells in
the splenic T zone. The results demonstrate that a key
function of the LTa/b- and TNF-dependent stromal cells
is constitutive production of chemokines that strongly at-
tract resting lymphocytes, and they suggest that these
chemokines function with other properties of the stroma to
compartmentalize cells into follicles and T zones.
The chemokine receptor CXCR5 is expressed by all
mature B cells and is the only known receptor for BLC, an
efficacious attractant of resting B cells (13, 15, 16). Since
loss of CXCR5 is sufficient to disrupt organization of
splenic follicles (5), it is reasonable to suggest that the
Figure 4. Costaining of BP-31 stromal
cell subsets with MAdCAM-1 and CD35
(CR1) and normal follicular organization
and BP-3 expression in op/op mice. (A)
Spleen tissue from wild-type mice was sec-
tioned and stained to detect MAdCAM-1
(brown) and BP-3 (black; left and center
panels), or CD35 (brown) and BP-3 (red;
right panel). Arrows in center panel indicate
MAdCAM-1 and BP-3 double-stained
cells. The faint brown CD35 staining corre-
sponds to CD35high marginal zone B cells
and CD35low follicular B cells. Original
magnification: 310, 320, or 340, as indi-
cated. (B) Spleen tissue from wild-type (left)
or op/op (center and right) mice was sec-
tioned and stained to detect: IgM (brown)
and MOMA1 (red; left and center), or CD4
and CD8 (brown) and BP-3 (red; right).
Note the lack of MOMA11 MMM staining
in the op/op mutant. Original magnification:
310. CA, central arteriole; F, follicle; T, T
zone.
Figure 5. MZM indepen-
dence and B lymphocyte depen-
dence of BLC expression. (A)
Northern blot analysis of total
RNA isolated from spleen tis-
sue of op/op, TCR-b2/2d2/2
(TCR2/2), mMT (BCR2/2),
and RAG-12/2 mice, probed to
detect expression of BLC and
EF-1a. (B) Relative chemokine
mRNA levels as determined by
PhosphorImager analysis of the
Northern blot shown in A and
additional blots, after correcting
for differences in RNA loading
from the corresponding EF-1a
value.
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greatly reduced expression of BLC in TNF-, TNFR1-,
LTa-, and LTb-deficient mice directly contributes to the
disrupted organization of splenic follicles in these animals.
Polarized follicles also fail to form in lymph nodes of TNF-
deficient mice and in the nodes that develop under some
conditions in LT-deficient mice (6, 11, 12, 37, 49). The
finding that BLC expression is reduced in mesenteric
lymph nodes of LTbR-Ig–treated mice indicates that
LTa/b plays a role in directing BLC expression in lymph
nodes. However, whether BLC is likely to contribute to
the organization of B cells into lymph node follicles is pres-
ently unclear, since CXCR5 does not appear to be re-
quired (5).
SLC and ELC both stimulate cells through CCR7, a re-
ceptor expressed by T and B lymphocytes, and these
chemokines are the most efficacious attractants of T cells so
far described (21, 25, 27, 50). We propose that the severe
reduction in T zone SLC expression in LTa/b-deficient
mice directly contributes to the loss of normal T cell com-
partmentalization in these animals. Maturing DCs upregu-
late CCR7 and have been suggested to migrate to lym-
phoid tissues in response to CCR7 ligands (51), making it
possible that the decrease in SLC also leads to reduced ac-
cumulation of mature DCs in the T zone. Consistent with
this possibility, lymph nodes developing in mice with re-
duced LTa levels have threefold fewer DCs than controls
(52), and we have observed a similar decrease in DC fre-
quency in LTa-deficient mouse spleens (our unpublished
observations). Reduced DC accumulation may be at least
partially responsible for the decreased expression of ELC, a
chemokine made by T zone DCs (27). The lowered ELC
levels are likely to exacerbate the effect of SLC deficiency
and contribute to the loss of T zone organization. TNF and
TNFR1 are also required for maximal SLC and ELC ex-
pression. However, mice deficient in TNF or TNFR1 do
continue to express significant amounts of SLC and ELC,
and this is consistent with the relatively unaffected T zone
organization in these mutant animals (3, 4, 6, 53). The gen-
erally greater reduction of chemokine expression in TNF-
deficient compared with TNFR1-deficient mice should
not be due to background gene effects, since all the animals
were generated on the C57BL/6 background; a more
likely possibility is that TNFR2 transmits some of the TNF
signals necessary for chemokine expression. In support of
this possibility is the finding that Langerhans cell migration
to lymph nodes is depressed in TNFR2-deficient mice
(54). Interestingly, during the analysis of several TNFR1-
deficient mice that had been housed in a conventional
animal facility, we found that whereas BLC and SLC levels
remained depressed, ELC expression was equal to the wild-
type controls (our unpublished observations). These obser-
vations are similar to other findings indicating that some of
the nonredundant functions of TNF in the resting state can
be overcome during an immune response (43).
The deficiency of FDCs in LT- and TNF-deficient mice
has been well characterized (1). Ultrastructural studies have
demonstrated that FDCs are part of a broader network of
follicular stromal cells (55), and using the molecule BP-3 as
a marker it has been possible to show that this more exten-
sive stromal cell network is also LT and TNF dependent
(see Fig. 3). Elegant bone marrow chimera and adoptive
transfer experiments have established that FDC develop-
ment requires TNFR1 and LTbR expression by the follic-
ular stroma and cytokine (LT and TNF) expression by he-
matopoietic cells, in particular B cells (39, 46–48). The
necessity for B cells in the maximal expression of BLC (see
Fig. 5) is consistent with these results and suggests that a
feedback loop exists which helps to keep the number of
BLC producing follicular stromal cells in proportion to the
number of B cells. The more depressed BLC expression in
LTa- and LTb-deficient mice than in B cell–deficient ani-
mals is also in agreement with studies showing that B cells
cannot be the sole source of LTa/b for follicle formation
(47, 48). Perhaps the LTa/b-expressing CD41CD32 cells
that enter lymphoid tissues early in development (56) in-
duce stromal cells to express BLC. Requirements for devel-
opment of T zone stromal cells have been less well charac-
terized than for FDCs, but our results indicate they are
similar in being TNF and LTa/b dependent. Experiments
are ongoing to address whether T cells, B cells, or other
cell types must express TNF or LTa/b for induction of
normal SLC expression. At this stage, it has not been possi-
ble to determine whether LT and TNF work directly to
induce chemokine expression or whether they function
further upstream, inducing and maintaining the develop-
ment and viability of chemokine-expressing stromal cells.
Although treatment of adult mice with soluble LTbR-Ig
leads within 1 wk to decreased expression of BLC and
SLC, the treatment also leads to rapid disruption of stromal
cells as defined by a variety of markers (36; and see Fig. 3).
Future studies must define in more detail the subpopula-
tions of LT- and TNF-dependent stromal cells that express
BLC and SLC and characterize the signaling pathways that
control chemokine expression.
The studies in this report have established a major role
for LTa/b, and a lesser but significant role for TNF, in
promoting the function of chemokine-expressing stromal
cells in lymphoid areas of the spleen. Analysis of lymph
nodes from LTbR-Ig–treated mice has provided initial ev-
idence that LTa/b is also required for normal chemokine
expression in lymph nodes. Given the requirement for
LTa/b and TNF in normal organization of all peripheral
lymphoid tissues, as well as the ability of ectopically ex-
pressed LTa to promote accumulation of B and T lympho-
cytes in lymphoid aggregates (57), it appears likely that
LTa/b and TNF function broadly in regulating lymphoid
tissue chemokine expression. Accumulation at nonlym-
phoid sites of cells in follicle- and T zone–like structures
also typifies several human diseases, including rheumatoid
arthritis and type I diabetes, and the possibility that locally
produced LT and TNF induce the development of BLC-
and SLC-expressing stromal cells deserves investigation.
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